262 related articles for article (PubMed ID: 31895498)
1. The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features.
Heidari Z; Harati-Sadegh M; Arian A; Maruei-Milan R; Salimi S
IUBMB Life; 2020 May; 72(5):922-930. PubMed ID: 31895498
[TBL] [Abstract][Full Text] [Related]
2. Analysis of polymorphisms, promoter methylation, and mRNA expression profile of maternal and placental P53 and P21 genes in preeclamptic and normotensive pregnant women.
Harati-Sadegh M; Kohan L; Teimoori B; Mehrabani M; Salimi S
J Biomed Sci; 2019 Nov; 26(1):92. PubMed ID: 31703578
[TBL] [Abstract][Full Text] [Related]
3. TP53 (rs1042522, rs28934571) and TP21 (rs1801270, rs1059234) Polymorphisms and Risk of Breast Cancer among Rural Women of Maharashtra: Findings from a Hospital Based Case- Control Study.
Datkhile KD; Bhosale SJ; Durgawale PP; Jagdale NJ; More AL; Gudur RA; Gudur AK; Patil SR
Asian Pac J Cancer Prev; 2023 May; 24(5):1611-1619. PubMed ID: 37247280
[TBL] [Abstract][Full Text] [Related]
4. The effects of the genetic polymorphisms of antioxidant enzymes on susceptibility to papillary thyroid carcinoma.
Salimi S; Harati-Sadegh M; Eskandari M; Heidari Z
IUBMB Life; 2020 May; 72(5):1045-1053. PubMed ID: 32031754
[TBL] [Abstract][Full Text] [Related]
5. The effect of CASP3 rs4647610 and rs4647602 polymorphisms on tumour size and cancer stage in papillary thyroid carcinoma.
Heidari Z; Eskandari M; Aryan A; Rostamzad F; Salimi S
Br J Biomed Sci; 2020 Jul; 77(3):129-134. PubMed ID: 32151194
[TBL] [Abstract][Full Text] [Related]
6. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study.
Maruei-Milan R; Heidari Z; Salimi S
J Cell Physiol; 2019 Aug; 234(8):12934-12940. PubMed ID: 30548972
[TBL] [Abstract][Full Text] [Related]
7. Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Carcinoma: A Case-Control Study.
Chen P; Sun R; Pu Y; Bai P; Yuan F; Liang Y; Zhou B; Wang Y; Sun Y; Zhu J; Zhang L; Gao L
Medicine (Baltimore); 2015 Sep; 94(38):e1536. PubMed ID: 26402809
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in selected DNA repair genes and cell cycle regulating genes involved in the risk of papillary thyroid carcinoma.
Halkova T; Dvorakova S; Sykorova V; Vaclavikova E; Vcelak J; Vlcek P; Sykorova P; Kodetova D; Betka J; Lastuvka P; Bavor P; Hoch J; Katra R; Bendlova B
Cancer Biomark; 2016 Jun; 17(1):97-106. PubMed ID: 27314298
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma.
Akulevich NM; Saenko VA; Rogounovitch TI; Drozd VM; Lushnikov EF; Ivanov VK; Mitsutake N; Kominami R; Yamashita S
Endocr Relat Cancer; 2009 Jun; 16(2):491-503. PubMed ID: 19286843
[TBL] [Abstract][Full Text] [Related]
10. Association between Genetic Polymorphisms in microRNA Machinery Genes and Risk of Papillary Thyroid Carcinoma.
Mohammadpour-Gharehbagh A; Heidari Z; Eskandari M; Aryan A; Salimi S
Pathol Oncol Res; 2020 Apr; 26(2):1235-1241. PubMed ID: 31250375
[TBL] [Abstract][Full Text] [Related]
11. Effects of the MTOR and AKT1 genes polymorphisms on papillary thyroid cancer development.
Maruei-Milan R; Saravani M; Heidari Z; Asadi-Tarani M; Salimi S
IUBMB Life; 2020 Dec; 72(12):2601-2610. PubMed ID: 33107190
[TBL] [Abstract][Full Text] [Related]
12. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
13. Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer.
Yuan Q; Bu Q; Li G; Zhang J; Cui T; Zhu R; Mu D
Clin Endocrinol (Oxf); 2016 Apr; 84(4):564-70. PubMed ID: 26052935
[TBL] [Abstract][Full Text] [Related]
14. TP53 and p21 (CDKN1A) polymorphisms and the risk of systemic lupus erythematosus.
Macedo JMB; Silva AL; Pinto AC; Landeira LFL; Portari EA; Santos-Rebouças CB; Klumb EM
Adv Rheumatol; 2023 Aug; 63(1):43. PubMed ID: 37605254
[TBL] [Abstract][Full Text] [Related]
15. MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.
Roncevic J; Djoric I; Selemetjev S; Jankovic J; Dencic TI; Bozic V; Cvejic D
Pathology; 2019 Jan; 51(1):55-61. PubMed ID: 30497805
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic polymorphisms, mRNA expression of p53 and p21 with chronic benzene poisoning in a chinese occupational population.
Sun P; Qiu Y; Zhang Z; Wan J; Wang T; Jin X; Lan Q; Rothman N; Xia ZL
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1821-8. PubMed ID: 19505915
[TBL] [Abstract][Full Text] [Related]
17. Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer.
Jeong S; Lee J; Kim D; Seol MY; Lee WK; Jeong JJ; Nam KH; Jung SG; Shin DY; Lee EJ; Chung WY; Jo YS
Medicine (Baltimore); 2016 Jan; 95(4):e2592. PubMed ID: 26825907
[TBL] [Abstract][Full Text] [Related]
18. Association between x-ray repair cross-complementing group 3 (XRCC3) genetic polymorphisms and papillary thyroid cancer susceptibility in a Chinese Han population.
Yuan K; Huo M; Sun Y; Wu H; Chen H; Wang Y; Fu R
Tumour Biol; 2016 Jan; 37(1):979-87. PubMed ID: 26264616
[TBL] [Abstract][Full Text] [Related]
19. Association between microRNA polymorphisms and papillary thyroid cancer susceptibility.
Dong G; Zhang R; Xu J; Guo Y
Int J Clin Exp Pathol; 2015; 8(10):13450-7. PubMed ID: 26722556
[TBL] [Abstract][Full Text] [Related]
20. TSHR rs2288496 associated with thyroid hormone and predict the occurrence of lymph node metastasis of papillary thyroid cancer.
Su X; Lin LW; Weng JL; Chen SW; Yang XH; Zhou DL; Long YK; Shao Q; Ye ZL; Peng JL; Deng L; He CY; Yang AK
Cancer Biomark; 2019; 26(4):461-470. PubMed ID: 31658048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
